MTOR and acute myeloid leukemia: Accordingly, the inhibition of aminopeptidases by CHR79888 (the active metabolite of tosedostat) induced a typical amino acid deprivation response (AADR) in HL-60 AML cells, including the inhibition of mTOR phosphorylation, reducing the protein synthesis and accumulation of intracellular peptides [27].